APLS vs GILD · rev $1.00B vs P/E 18, rev $7.80B
Apellis Pharmaceuticals Inc (APLS) versus Gilead Sciences Inc (GILD) — a side-by-side from cached financials, not a winner call.
Apellis Pharmaceuticals Inc (APLS) is a biotechnology company listed on US.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US. It is led by Daniel P. O'Day.
Latest reported APLS revenue for 2025-12-31 was $1.00B. Net income was $22.4M. Revenue was up 28.5% from 2024-12-31 to 2025-12-31. APLS currently screens at market cap $2.29B.
Latest reported GILD revenue for 2026-06-30 was $7.80B. Net income was -$10.50B. Revenue was up 12.1% from 2026-03-31 to 2026-06-30. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
APLS currently screens at market cap $2.29B. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Not investment advice. Open the APLS and GILD stock pages for the full models.
Not investment advice.